Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HS022 versus trastuzumab, each combined with vinorelbine, in HER2-positive metastatic breast cancer
ChiCTR2300072390Phase 3Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HS022 in breast cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Best overall response rate (ORR24). Started May 2018; status: completed.
02
Drugs
HS022
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300072390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072390.